ArticleMemorias do Instituto Oswaldo Cruz2013
Imatinib activity on Schistosoma mansoni.
Article in Memorias do Instituto Oswaldo Cruz, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Identification of 6-(piperazin-1-yl)-1,3,5-triazine as a chemical scaffold with broad anti-schistosomal activities.Wellcome open research · 2020Article
- Study of therapeutic effect of different concentrations of imatinib on Balb/c model of cutaneous leishmaniasis.AIMS microbiology · 2020Article
- Article
- Evaluation of Different Concentrations of Imatinib on the Viability ofAdvanced biomedical research · 2019Article
- Computationally-guided drug repurposing enables the discovery of kinase targets and inhibitors as new schistosomicidal agents.PLoS computational biology · 2018Article
- Defining the Schistosoma haematobium kinome enables the prediction of essential kinases as anti-schistosome drug targets.Scientific reports · 2015Article
- Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration-Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal.The Journal of infectious diseases · 2015Article
- Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma mansoni.Parasites & vectors · 2015Article
- Anthelmintic activity in vivo of epiisopiloturine against juvenile and adult worms of Schistosoma mansoni.PLoS neglected tropical diseases · 2015Article
- Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib.International journal for parasitology. Drugs and drug resistance · 2014Article
- Repurposing drugs for the treatment and control of helminth infections.International journal for parasitology. Drugs and drug resistance · 2014Review
- Imatinib treatment causes substantial transcriptional changes in adult Schistosoma mansoni in vitro exhibiting pleiotropic effects.PLoS neglected tropical diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imatinib, a drug used for treatment of human chronic myeloid leukaemia, due to its activity against protein kinases, has been also evaluated in vitro against Schistosoma mansoni showing high schistosomicidal activity. In the present experiments imatinib activity in vitro was confirmed at the doses of 25 µM, 50 µM and 100 µM. The first drug activity observed with the lower dose was interruption of egg-laying and with the higher dosages was the death of the worms. In mice infected with S. mansoni no activity was found even with 1,000 mg/kg/day, 500 mg/kg/day, single oral dose or when administered for three consecutive days. This is another example of the difference of results related to in vitro and in vivo trials using S. mansoni worms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.